Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jonathan Barasch is active.

Publication


Featured researches published by Jonathan Barasch.


Kidney International | 2012

NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease

Thomas L. Nickolas; Catherine S. Forster; Meghan E. Sise; Nicholas Barasch; David Sola-Del Valle; Melanie Viltard; Charles Buchen; Shlomo Kupferman; Maria Luisa Carnevali; Michael Bennett; Silvia Mattei; Achiropita Bovino; Lucia Argentiero; Andrea Magnano; Prasad Devarajan; Kiyoshi Mori; Hediye Erdjument-Bromage; Paul Tempst; Landino Allegri; Jonathan Barasch

The rate of progression of chronic kidney disease (CKD) is difficult to predict using single measurements of serum creatinine or proteinuria. On the other hand, documented tubulointerstitial disease presages worsening CKD, but kidney biopsy is not practical for routine use and generally does not sample the tubulointerstitial compartment of the medulla. Perhaps a urine test that correlates with specific histological findings may serve as a surrogate for the kidney biopsy. Here we compared both immunoblot analysis (under non-reducing conditions) and a commercially available monomer immunoassays of Neutrophil Gelatinase Associated Lipocalin (NGAL) with pathological changes found in kidney biopsies, to determine whether specific histological characteristics associated with a specific NGAL species. We found that the urine of patients with advanced CKD contained NGAL monomers as well as higher molecular weight complexes containing NGAL, identified by MALDI-TOF/TOF mass spectroscopy. The NGAL monomer significantly correlated with glomerular filtration rate, interstitial fibrosis and tubular atrophy. Hence, specific assays of the NGAL monomer implicate histology associated with progressive, severe CKD.The type and the extent of tissue damage inform the prognosis of chronic kidney disease (CKD), but kidney biopsy is not a routine test. Urinary tests that correlate with specific histological findings might serve as surrogates for the kidney biopsy. We used immunoblots and ARCHITECT-NGAL assays to define the immunoreactivity of urinary neutrophil gelatinase-associated lipocalin (NGAL) in CKD, and we used mass spectroscopy to identify associated proteins. We analyzed kidney biopsies to determine whether specific pathological characteristics associated with the monomeric NGAL species. Advanced CKD urine contained the NGAL monomer as well as novel complexes of NGAL. When these species were separated, we found a significant correlation between the NGAL monomer and glomerular filtration rate (r=-0.53, P<0.001), interstitial fibrosis (mild vs. severe disease; mean 54 vs. 167 μg uNGAL/g Cr, P<0.01), and tubular atrophy (mild vs. severe disease; mean 54 vs. 164 μg uNGAL/g Cr, P<0.01). Monospecific assays of the NGAL monomer demonstrated a correlation with histology that typifies progressive, severe CKD.


Nephrology Dialysis Transplantation | 2011

Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy

David Sola-Del Valle; Sumit Mohan; Jen-Tse Cheng; Neal Paragas; Meghan E. Sise; Vivette D. D’Agati; Jonathan Barasch

BACKGROUNDnUrinary neutrophil gelatinase-associated lipocalin (uNGAL) is expressed by kidney tubules that are acutely damaged, but few studies have investigated the association of neutrophil gelatinase-associated lipocalin (NGAL) with different forms of chronic kidney disease (CKD). HIV-associated nephropathy (HIVAN) is a progressive form of CKD characterized by collapsing focal segmental glomerulosclerosis and microcytic tubular dilatation that typically leads to end-stage renal disease (ESRD).nnnMETHODSnPreviously, we reported that microcystic tubular dilatations specifically expressed NGAL RNA, implying that the detection of uNGAL protein could mark advanced HIVAN. To test this idea, we performed a comparative study of diverse proteinuric glomerulopathies in 25 patients who were HIV positive.nnnRESULTSnEighteen patients had HIVAN and seven had other glomerulopathies (four membranoproliferative glomerulonephritis, one membranous glomerulonephritis, one amyloid and one malarial GN). HIVAN and non-HIVAN patients did not differ with respect to age, ethnicity, serum creatinine, estimated GFR, proteinuria or the prevalence of hypocomplementemia (6 versus 29%, P = 0.18), but HIVAN patients were less likely to have HCV infections. HIVAN patients expressed 4-fold higher levels of uNGAL than the patients with other glomerulopathies [387 ± 338 versus 94 ± 101 μg/g urine creatinine (uCr), P = 0.02]. A cutpoint of 121.5 μg uNGAL/g uCr demonstrated 94% sensitivity and 71% specificity for the diagnosis of HIVAN, with an area under the receiver operator characteristic curve of 0.88.nnnCONCLUSIONnIn summary, while HIVAN disease is currently diagnosed only by kidney biopsy, uNGAL can distinguish HIVAN from other proteinuric glomerulopathies in the HIV-infected patient, likely because of its specific expression from characteristic microcysts.


Kidney International | 2009

Elevated urine neutrophil gelatinase-associated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases.

Meghan E. Sise; Jonathan Barasch; Prasad Devarajan; Thomas L. Nickolas

To the Editor: Hsu et al. evaluated the association between chronic kidney disease (CKD) and risk of acute kidney injury (AKI). They demonstrated several important findings: (1) CKD is an important risk factor for the development of AKI; (2) even early CKD stage 3 kidney dysfunction is a risk factor for the development of AKI; and (3) AKI risk increased in a step-wise relationship with worsening kidney disease.1 The public health implication of their investigation is immense. In 2000, 20 million adults in the United States were affected by kidney disease,2 and as the prevalence of CKD increases, the incidence of AKI will also continue to increase.3


Journal of the American College of Cardiology | 2014

SODIUM-RESTRICTED DIETARY APPROACHES TO STOP HYPERTENSION DIET INCREASES EARLY MARKERS OF RENAL TUBULAR INJURY IN HYPERTENSIVE HEART FAILURE WITH PRESERVED EJECTION FRACTION

Jeffrey D. Wessler; Mathew S. Maurer; Jonathan Barasch; Scott Hummel

The sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) lowers systemic blood pressure and favorably affects cardiac and vascular function in hypertensive heart failure with preserved ejection fraction (HFPEF). Dietary sodium restriction reduces renal damage in HFPEF animal


Archive | 2004

Method and kit for detecting the early onset of renal tubular cell injury

Prasad Devarajan; Jonathan Barasch


Archive | 2005

Detection of ngal in chronic renal disease

Jonathan Barasch; Prasad Devarajan; Thomas L. Nickolas; Kiyoshi Mori


Archive | 2006

Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis

Vikas P. Sukhatme; S. Ananth Karumanchi; Pankaj Seth; Jun-ichi Hanai; Jonathan Barasch; Kiyoshi Mori


Archive | 2011

Transgenic Reporter Mouse and Method for Use

Neal Paragas; Jonathan Barasch; Andong Qiu


Archive | 2012

NGAL FOR DIAGNOSIS OF RENAL CONDITIONS

Prasad Devarajan; Jonathan Barasch


Archive | 2009

Ngal à poids moléculaire élevé en tant que biomarqueur pour une maladie rénale chronique

Jonathan Barasch; Nicholas Barasch

Collaboration


Dive into the Jonathan Barasch's collaboration.

Top Co-Authors

Avatar

Prasad Devarajan

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Kiyoshi Mori

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Thomas L. Nickolas

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicholas Barasch

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

David Sola-Del Valle

Massachusetts Eye and Ear Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catherine S. Forster

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Charles Buchen

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Hediye Erdjument-Bromage

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge